| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790422 | American Journal of Ophthalmology | 2018 | 26 Pages |
Abstract
This retrospective study supports that 2Â mg PF-IVTA displayed noninferior treatment duration to 4Â mg PF-IVTA, and may carry a significantly lower side-effect profile of cataract development and glaucoma filtering surgery.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Preethi S. Ganapathy, Careen Y. Lowder, Sruthi Arepalli, Kimberly Baynes, Manshi Li, James Bena, Sunil K. Srivastava,